These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 37458640)

  • 1. The association between fingolimod and mental health outcomes in a cohort of Multiple Sclerosis patients with stress.
    Gammoh OS; Al-Smadi A; Alqudah A; Al-Habahbeh S; Weshah F; Ennab W; Al-Shudifat AE; Bjørk MH
    Eur Rev Med Pharmacol Sci; 2023 Jul; 27(13):6018-6026. PubMed ID: 37458640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Depression, anxiety, insomnia and dysmenorrhea in stressed fingolimod-treated women with multiple sclerosis.
    Gammoh O; Ennab W
    Int J Psychiatry Med; 2024 Jan; 59(1):50-64. PubMed ID: 37465938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fingolimod and Dimethyl-Fumarate-Derived Lymphopenia is not Associated with Short-Term Treatment Response and Risk of Infections in a Real-Life MS Population.
    Boffa G; Bruschi N; Cellerino M; Lapucci C; Novi G; Sbragia E; Capello E; Uccelli A; Inglese M
    CNS Drugs; 2020 Apr; 34(4):425-432. PubMed ID: 32193826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FACTORS ASSOCIATED WITH SWITCHING FROM INJECTABLE TO ORAL DISEASE MODIFYING AGENTS AMONG PATIENTS WITH MULTIPLE SCLEROSIS.
    Li J; Chikermane SG; Earla JR; Hutton GJ; Aparasu RR
    Mult Scler Relat Disord; 2022 Apr; 60():103703. PubMed ID: 35278846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of and Risk Factors Associated With Mental Health Symptoms Among the General Population in China During the Coronavirus Disease 2019 Pandemic.
    Shi L; Lu ZA; Que JY; Huang XL; Liu L; Ran MS; Gong YM; Yuan K; Yan W; Sun YK; Shi J; Bao YP; Lu L
    JAMA Netw Open; 2020 Jul; 3(7):e2014053. PubMed ID: 32609353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients.
    Alping P; Askling J; Burman J; Fink K; Fogdell-Hahn A; Gunnarsson M; Hillert J; Langer-Gould A; Lycke J; Nilsson P; Salzer J; Svenningsson A; Vrethem M; Olsson T; Piehl F; Frisell T
    Ann Neurol; 2020 May; 87(5):688-699. PubMed ID: 32056253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-World Adherence and Persistence to Oral Disease-Modifying Therapies in Multiple Sclerosis Patients Over 1 Year.
    Johnson KM; Zhou H; Lin F; Ko JJ; Herrera V
    J Manag Care Spec Pharm; 2017 Aug; 23(8):844-852. PubMed ID: 28737986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time to treatment failure following initiation of fingolimod versus teriflunomide for multiple sclerosis: a retrospective US claims study.
    Vieira MC; Conway D; Cox GM; Peeples M; Bensimon AG; Macheca M; Herrera V
    Curr Med Res Opin; 2020 Feb; 36(2):261-270. PubMed ID: 31694401
    [No Abstract]   [Full Text] [Related]  

  • 9. Factors associated with oral fingolimod use over injectable disease- modifying agent use in multiple sclerosis.
    Earla JR; Hutton GJ; Thornton JD; Chen H; Johnson ML; Aparasu RR
    Explor Res Clin Soc Pharm; 2021 Jun; 2():100021. PubMed ID: 35481133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment.
    Vollmer BL; Nair K; Sillau S; Corboy JR; Vollmer T; Alvarez E
    Ann Clin Transl Neurol; 2020 Sep; 7(9):1466-1476. PubMed ID: 32767538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis.
    Fox RJ; Chan A; Zhang A; Xiao J; Levison D; Lewin JB; Edwards MR; Marantz JL
    Curr Med Res Opin; 2017 Feb; 33(2):175-183. PubMed ID: 27733070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mental health impacts among health workers during COVID-19 in a low resource setting: a cross-sectional survey from Nepal.
    Khanal P; Devkota N; Dahal M; Paudel K; Joshi D
    Global Health; 2020 Sep; 16(1):89. PubMed ID: 32977818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence and Risk of Infection Associated With Fingolimod in Patients With Multiple Sclerosis: A Systematic Review and Meta-Analysis of 8,448 Patients From 12 Randomized Controlled Trials.
    Zhao Z; Ma CL; Gu ZC; Dong Y; Lv Y; Zhong MK
    Front Immunol; 2021; 12():611711. PubMed ID: 33763062
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment retention on fingolimod compared with injectable multiple sclerosis therapies in African-American patients: A subgroup analysis of a randomized phase 4 study.
    Cascione M; Tenenbaum N; Wendt J; Meng X; Schofield L; Cree BAC;
    Mult Scler Relat Disord; 2018 Oct; 25():50-56. PubMed ID: 30036854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment.
    Hatcher SE; Waubant E; Nourbakhsh B; Crabtree-Hartman E; Graves JS
    JAMA Neurol; 2016 Jul; 73(7):790-4. PubMed ID: 27135594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of depression in multiple sclerosis across disease-modifying therapies.
    Longinetti E; Frisell T; Englund S; Reutfors J; Fang F; Piehl F
    Mult Scler; 2022 Apr; 28(4):632-641. PubMed ID: 34264143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistence and adherence to the new oral disease-modifying therapies for multiple sclerosis: A population-based study.
    Setayeshgar S; Kingwell E; Zhu F; Zhang T; Carruthers R; Marrie RA; Evans C; Tremlett H
    Mult Scler Relat Disord; 2019 Jan; 27():364-369. PubMed ID: 30476872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Depression, anxiety symptoms, Insomnia, and coping during the COVID-19 pandemic period among individuals living with disabilities in Ethiopia, 2020.
    Necho M; Birkie M; Gelaye H; Beyene A; Belete A; Tsehay M
    PLoS One; 2020; 15(12):e0244530. PubMed ID: 33378397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study.
    Cohen M; Maillart E; Tourbah A; De Sèze J; Vukusic S; Brassat D; Anne O; Wiertlewski S; Camu W; Courtois S; Ruet A; Debouverie M; Le Page E; Casez O; Heinzlef O; Stankoff B; Bourre B; Castelnovo G; Rico A; Berger E; Camdessanche JP; Defer G; Clavelou P; Al Khedr A; Zephir H; Fromont A; Papeix C; Brochet B; Pelletier J; Lebrun C;
    JAMA Neurol; 2014 Apr; 71(4):436-41. PubMed ID: 24566807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors associated with perceived need for mental health care in multiple sclerosis.
    Orr J; Bernstein CN; Graff LA; Patten SB; Bolton JM; Sareen J; Marriott JJ; Fisk JD; Marrie RA;
    Mult Scler Relat Disord; 2018 Oct; 25():179-185. PubMed ID: 30096684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.